Brief: Ns Pharma Announces FDA Clearance To Initiate Phase Ii Study For Ns-089/Ncnp-02, An Exon 44 Skipping Candidate For Treatment Of Duchenne Muscular Dystrophy
14/04/2023 14:58
April 14 (Reuters) - Nippon Shinyaku Co Ltd 4516.T :
* NS PHARMA ANNOUNCES FDA CLEARANCE TO INITIATE PHASE II
STUDY FOR
NS-089/NCNP-02, AN EXON 44 SKIPPING CANDIDATE FOR TREATMENT OF
DUCHENNE MUSCULAR DYSTROPHY
Source text for Eikon: ID:nPn4PhWX2a
Further company coverage: 4516.T
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nippon Shinyaku
See all newsTable: Nippon Shinyaku -Q1 group results (IFRS)
Brief: Elixirgen Therapeutics And Nippon Shinyaku Enter Into An Option Agreement For The Development And Commercialization Of Exg-7001 For Duchenne Muscular Dystrophy
Table: Nippon Shinyaku -2025/26 group results (IFRS)
Table: Nippon Shinyaku -2025/26 parent results
Table: Nippon Shinyaku -9-MTH group results (IFRS)